Skip Navigation

Phase I/II, Double-Blind, Placebo-Controlled, Dose Escalation and Expansion Study of ALVR106 for the Treatment of High-Risk Patients With Respiratory Viral Infections After Hematopoietic Cell Transplant

Brief Summary

Hematologic - Other

Study Type:

I/II Identifier:

Study #:

Start Date:
Feb 22, 2022

Full Details and Eligibility at

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below. ID: NCT04933968

View Complete Trial Details & Eligibility at